Opto Circuits India today said it has received an approval from the USFDA to market a new modular patient monitoring system -- eVision 9100-- in the US market.
The approval has been granted to the firm's US subsidiary, Criticare Systems Inc, by the US Food and Drug Administration (USFDA), the company said in a statement.
"The US FDA clearance will now enable us to commercialise eVision 9100 in the US and will help boost sales in other parts of the world," Opto Circuits (India) Chairman and Managing Director Vinod Ramnani said.
The new device, eVision 9100, measures physiological parameters of patients, which can be removed or changed without interruptions to the operating system, it said.
It also provides physiological data, systems alarms and patient data analysis to the care providers.
"Multi-parameter monitors have the largest share in the patient monitoring market. A US FDA cleared modular vital signs monitor in our portfolio will help us capitalise on the market potential," Ramnani added.
The global revenue for multi parameter patient monitors is estimated to be around $2.25 billion, it added.
Opto Circuts (India) designs, manufactures and markets non-invasive healthcare equipment and invasive vascular products.
The shares of the company were trading at Rs 283.40 at BSE in the afternoon trade up by 1.40 per cent from it's previous close.
